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Abstract
Background: The translation of novel genomic technologies from bench to bedside enjoins the comprehensive
consideration of the perspectives of all stakeholders who stand to influence, or be influenced by, the translational
course. Non-invasive prenatal aneuploidy testing that utilizes cell-free fetal DNA (cffDNA) circulating in maternal
blood is one example of an innovative technology that promises significant benefits for its intended end users;
however, it is currently uncertain whether it will achieve widespread clinical implementation. We conducted
qualitative interviews with 18 diverse stakeholders in this domain, including prospective users of the technology
and healthcare personnel, researchers and developers, and experts in social, legal, and regulatory aspects of
genetic technology, and a pilot survey of 62 obstetric healthcare providers. Analysis of interview and survey data
was combined with a review of the proceedings of a full-day, multidisciplinary conference on the topic and
published scientific and ethics literature surrounding this and other relevant technologies.
Discussion: We constructed potential pathways for technological implementation, identified broad stakeholder
classes party to these translational processes, and performed a preliminary assessment of the viewpoints and
interrelations among these diverse stakeholders. Some of the stakeholders whose priorities are critical to
understand and integrate into translation include pregnant women and their families; healthcare providers;
scientists, their institutions or companies, and the funding agencies that support them; regulatory and judicial
bodies; third-party payers; professional societies; educational systems; disability rights communities; and other
representatives from civil society. Stakeholder interviews, survey findings, and conference proceedings add
complexity to these envisioned pathways and also demonstrate a paramount need to incorporate an iterative
stakeholder analysis early and throughout the translational endeavor. We believe that the translational framework
that we have developed will help guide crucial future stakeholder mapping and engagement activities for cffDNA
aneuploidy testing and inform novel methods of technology assessment for other developments in the growing
field of genomic medicine.
Summary: Mapping potential pathways for implementation and exploring the attitudes and interrelations of
diverse stakeholders may lead to more effective translation of a novel method of prenatal aneuploidy testing.
Background
The 2011 vision of the National Human Genome
Research Institute aspires to fulfill the ultimate goal of
the Human Genome Project by applying the results of
genomic research to diverse areas of healthcare [1]. How-
ever, this vision appears to be based on the assumption
that translation is primarily a matter of greater understand-
ing of biology and development of genomic technology.
Instead, we suggest that successful genomic translation
also requires the design of translational pathways that take
into account the objectives and values of a wide range of
stakeholders. Because translation of medical technologies
rarely proceeds down a path of inevitable advances, we
propose that translation is more likely when all stakeholder
perspectives are deeply integrated into each phase of the
research, development, implementation, and policy-making
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process [2-8]. To be successful, these pathways must addi-
tionally be mindful of broader context: the existence of
related technologies, social dynamics and stakeholder con-
victions about these technologies, and existing political and
economic frameworks for translation and use. As evi-
denced by the thwarted translation of other promising
genetic technologies, such as genetically modified crops
and gene transfer technologies, a failure to explore contex-
tual elements in advance of translation may result in unful-
filled stakeholder expectations, stakeholder frustration and
resistance, and ultimately, translational failure, even after a
new biotechnology has been made commercially available
[9-11].
By exploring potential translational pathways in the con-
text of one nascent application of genetic technology -
prenatal aneuploidy testing using cell-free fetal DNA
(cffDNA) - we illustrate how stakeholder perspectives may
have significant and direct effects on the course of transla-
tion. We hope that the development of this framework of
translational pathways and stakeholder interactions
provides impetus for a more textured evaluation of the
influences and interests of diverse stakeholders and con-
tinuous engagement of these actors in implementing
cffDNA technology. Furthermore, we believe that this
broad methodology for technology assessment - moving
beyond evaluation of the primary characteristics of a tech-
nology towards a comprehensive integration of stake-
holder values and contextual elements - may be applied to
other genomic technologies with unique sets of stake-
holders and divergent translational pathways.
Tracing translational pathways for cffDNA testing for
aneuploidy
Several recent studies have demonstrated that cffDNA in
maternal blood can be used for the non-invasive prenatal
detection of aneuploidy [12-16]. Because this testing
requires only a maternal blood draw - eliminating any risk
of miscarriage - and can be performed earlier in pregnancy
than existing tests, cffDNA testing has the potential to
make aneuploidy testing routine for all pregnancies. Sev-
eral companies have announced plans to commercialize
cffDNA testing for aneuploidy, including trisomy 13, 18,
and 21 (Down syndrome), and three companies have
already started to offer trisomy testing in the United States
[17-20]. Although substantial media attention has been
directed towards the introduction of these tests, it is not
clear whether the development of this technology will lead
to the immediate and widespread adoption that some
observers predict [21].
This analysis has been conducted to explore the under-
lying values of diverse actors in the research, development,
and use of cffDNA technology in order to guide the trans-
lational enterprise [22-24]. As the first stage in this assess-
ment, we interviewed 18 stakeholders with diverse
interests in this realm to sketch the landscape of the tech-
nology and its ethical, legal, and social context and to
understand how various stakeholders conceptualize trans-
lation. Stakeholders were identified as representatives of
previously described parties to genetic technology transla-
tion, including prospective technology adopters, various
healthcare personnel, academic researchers, commercial
developers, community activists, and experts on law and
regulation in this arena, through citation in the academic
literature and media and via snowball sampling [4,24,25].
Semi-structured interviews were conducted, lasting
approximately one hour each. We also conducted a pilot
survey of 62 healthcare providers in attendance at a Conti-
nuing Medical Education conference on advances in
obstetrics and gynecology; the findings from this survey
have been published elsewhere but are provided as impor-
tant references for this analysis [26]. Our Institutional
Review Board approved both the series of interviews and
survey, and all interview and survey subjects provided con-
sent to participate. We also reviewed the transcripts of a
full-day, multi-disciplinary conference, ‘The Coming Revo-
lution in Prenatal Genetic Testing? Scientific, Ethical,
Social, and Policy Responses to Maternal Serum Cell-free
Fetal DNA Testing’, jointly hosted by the Stanford Univer-
sity School of Medicine and Stanford Law School in May
2010, and pertinent academic literature on cffDNA testing,




Throughout data collection and review, we began to nar-
row in on six classes of relevant stakeholders while tracing
how the technology might be translated from bench to
bedside. Iterative feedback from colleagues knowledgeable
about the technology confirmed that our framework was a
legitimate and useful tool for identifying stakeholders and
assessing their influences and interrelations in the transla-
tional context. The findings of our interviews, survey, and
the multi-disciplinary conference add nuance to many of
the translational complexities and contingencies set forth
by the National Human Genome Research Institute’s
vision and inform the specific translational pathways that
we describe. These data suggest that a wide range of scien-
tific and social factors, including characteristics of the
existing system of prenatal care and testing but beyond
simply the technical characteristics of cffDNA testing, may
affect implementation.
In the following sections, organized by our six identi-
fied stakeholder classes, we sketch potential translational
pathways for cffDNA testing for aneuploidy, including
their points of divergence, and the individuals and insti-
tutions that influence, and may be influenced by, their
progress. Increasingly complex diagrams of these
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pathways (Figures 1 to 6) are presented as additional
sets of stakeholder interactions are explored. These
pathways are not mutually exclusive but are delineated
in order to highlight their salient features and ethical,
legal, and social consequences for stakeholders. Where
appropriate, concrete policy recommendations are
presented.
Resource allocation
Funding for the research, development, and initial applica-
tion of a technology is necessary to any translational
endeavor (Figure 1). The allocation of resources for the
translation of cffDNA testing demands sufficient expecta-
tion that the current uncertainties regarding the promised
value of this technology will resolve favorably [27]. Addi-
tionally, mobilization of all resources - capital, equipment,
and personnel - will need to be scaled up throughout the
progression of implementation until it is clear whether or
not the technology can, and will, be applied in a wide-
spread manner.
Thus far, the majority of fiscal support for the research
phase of cffDNA testing, which is occurring primarily in
academic research centers, has been in the form of grants
or endowments from government agencies, private foun-
dations, and institutional funds. The biotechnology indus-
try has subsequently been pursuing the development of
scalable tests based upon research results using venture
capital, grants, and other investments [28-30]. Until rev-
enue can be secured, however, additional resources are
required to apply the technology in its intended use. Bio-
technology firms that are conducting studies to evaluate
the clinical application of cffDNA testing must be capable
of attracting sufficient financial support to underwrite
these activities. As cffDNA testing for aneuploidy becomes
clinically available, the source and size of capital invest-
ment will need to adjust to meet the changing priorities of
its commercializers and users [31]. Private and state health
insurance agencies have already become involved in dictat-
ing the implementation of this technology at the point of
care, through decisions of whether to cover the first com-
mercially available cffDNA tests for aneuploidy [32]. Given
insurers’ continued support for extant prenatal screening
and diagnostic techniques, it is essential to understand the
priorities of these funders in order to identify likely trajec-
tories for the translation of this new technology. State-
ments made by our study’s interviewees suggest that,
where possible, insurance coverage should be decided on
the basis of several inputs, including the wishes of insur-
ance program enrollees to receive testing, medical stan-
dard of care, and comprehensive comparative analyses to
existing technologies.
Research and development
Scientists at academic institutions have designed several
methods to test cffDNA for aneuploidy, and the biotech-
nology industry is currently aiming to validate these
methods through clinical trials (Figure 2) [16]. During
our stakeholder interviews, several scientists claimed
that reliable testing is already feasible in the presence of
skilled personnel and unlimited resources, which is con-
sistent with the growing body of literature [12-15].
However, in considering the scaling-up or expansion of
such testing to broader populations and resource-limited
settings, developers face the challenge of maintaining
sufficient levels of reliability to compete with existing,
highly reliable diagnostic tests. A similar technology,
which attempted to use fetal cells circulating in mater-
nal blood for prenatal diagnosis, showed some success
on a small scale, but a large trial failed to demonstrate
sufficiently robust results, resulting in the almost com-
plete rejection of the technology [33,34]. Initial evidence
for cffDNA testing for aneuploidy indicates that this
technology may achieve more promising outcomes;
however, ongoing validation and dissemination of study
results will be an important facet of successful clinical
implementation of this technology [12-15]. In both
interviews and the literature, we have witnessed several
physician calls for validation studies that are reproduci-
ble across populations of all risk levels and variable clin-
ical and laboratory conditions, which were ultimately








Figure 1 The allocation of resources to research and
development is a crucial factor in technology development.
Thick dashed arrows represent potential pathways for the flow of
technology, resources, and knowledge among primary groups of
stakeholders. Thin dashed arrows represent interactions and
influences among broader groups of stakeholders. The stakeholders
and pathways highlighted in red will be the focus of each section.
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Many researchers in this field hold dual roles as faculty
in academic laboratories and as executives, board mem-
bers, or consultants for biotechnology companies tasked
with commercializing cffDNA tests. Several of these indi-
viduals have been awarded patents for cffDNA testing
strategies, and the licensing and information-sharing
strategies of these patent holders have dictated which
biotechnology companies are in a position to translate
these methods into clinical applications. Thus far, these
companies have utilized their in-house laboratories to
conduct aneuploidy testing [13,36]. However, once a
satisfactory large-scale commercial test has been devel-
oped, it is unclear whether companies will require that all
samples be sent to their intramural laboratories for
testing (and whether they have the infrastructure for
such large-scale operations) or whether they will sub-
license their methods such that independent clinical
laboratories can perform the tests. In previous instances,
companies with rights to patents for specific genes have
stringently enforced monopolies through the threat of
lawsuits and limited the provision of commercial testing
to their internal laboratories [37].
If patent holders for cffDNA testing choose to restrict
licensing, there may be a significant impact on availabil-
ity of the technology, raising concerns of distributive
justice, in addition to the potentially troubling implica-
tions for provider and patient independence in clinical





























Figure 3 The route of provision of testing raises significant ethical and logistical questions.
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market exclusivity resulting from patents and restrictive
licensing strategies for genetic tests negatively impacts
development, cost, and access to testing [39,40]. The
ongoing judicial case challenging patents covering the
breast and ovarian cancer susceptibility genes BRCA1
and BRCA2, held by the company Myriad Genetics, may
thus have a significant effect on the course and implica-
tions of patenting for cffDNA testing if the validity of
patents on genes or genetic diagnostic technologies is
called into question [41]. Furthermore, because of the
possibility of overlap among existing patent claims sur-
rounding cffDNA testing, the enforcement of patents
through infringement suits may have a drastic effect on
the translational route of this testing. Despite the fact
that legislation, such as the Bayh-Dole Act, is intended
















































Figure 5 Legal, regulatory, and funding decisions by government agencies will change the testing landscape.
Sayres et al. Genome Medicine 2012, 4:49
http://genomemedicine.com/content/4/6/49
Page 5 of 11
biotechnology industry in just this way, enforcement of
patents on cffDNA testing may have the unintended
consequence of raising barriers to dissemination [42].
While protectable intellectual property is an important
and sometimes necessary incentive for product research
and development, relevant commercializers and policy-
makers should bear in mind the potential broad reper-
cussions of patenting and licensing practices on cffDNA
testing for aneuploidy [24].
Product dissemination
If biotechnology companies intend to conduct cffDNA
testing for aneuploidy through commercial laboratories,
the possibility of direct-to-consumer (DTC) test provision,
rather than provision through a healthcare professional,
arises (Figure 3). DTC genetic testing has inspired intense
debate as the medical community and the public try to
strike a balance between empowering individuals to learn
about their genetic makeup and protecting them from
information with an unsound scientific basis or unclear
health implications [43,44]. The current controversy over
the appropriateness of placing genetic information directly
in the hands of consumers becomes more pronounced
when decisions to continue or terminate a pregnancy may
result from inaccurate or misunderstood test results [45].
Responses to our pilot survey of obstetric healthcare provi-
ders demonstrate reservation about the potential availabil-
ity of DTC cffDNA testing, and furthermore, respondents
and interviewees alike indicated that they believe that
genetic counseling should be utilized in order for pregnant
women wishing to receive testing to understand this
technology’s indications, limitations, and implications [26].
A policy requiring comprehensive consent and counseling
procedures before provision of genetic testing would addi-
tionally be in line with the positions of several relevant
professional societies, including the American College of
Medical Genetics, the National Society of Genetic Counse-
lors, and the American Medical Association [46-48].
Existing cffDNA tests for trisomy 21 and RhD blood
group type are currently available only via physician refer-
ral, whereas non-invasive prenatal sex testing can be
ordered directly by a pregnant woman via the internet
[16,17]. With the exception of commercial trisomy 21
tests, no data on the uptake of cffDNA tests have been
made publicly available yet, so it is unclear how many tests
are being performed. In a previous study of obstetric pro-
viders, a majority reported moderate to low levels of
knowledge about availability of cffDNA testing, although
most were simultaneously interested in offering this type
of testing for aneuploidy [26].
Most predominant in dictating provider uptake of
cffDNA testing may be the recommendations put for-
ward by relevant professional societies, as surveyed
healthcare providers demonstrated nearly unanimous
reliance on such guidelines in future decision-making
surrounding the adoption of cffDNA testing [26]. Histori-
cally, rapid and widespread uptake of prenatal alpha-feto-
protein screening for neural tube defects was almost
exclusively the result of one statement issued by the legal
committee of American Congress of Obstetricians and
Gynecologists, despite its marked incompatibility with a
























Figure 6 Activists can place pressure on key stakeholders, which may directly affect translation.
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Moreover, this uptake occurred at a time when clinicians
were apprehensive about the limitations of such screen-
ing and were still calling for further studies and services
coordination before screening was accessed by broad
patient populations [49]. Fear of liability may ultimately
have driven implementation of this technology. In the
case of cffDNA testing for aneuploidy or other indica-
tions, professional societies should comprehensively con-
sider the ethical, legal, social, political, and economic
repercussions of testing before issuing unified messages
for their constituents.
A number of other factors will affect whether physicians
do ultimately offer these tests to their patients: whether a
physician order is required for testing, the reliability and
timing of the test, clinicians’ perception of effectiveness
and trust in the testing laboratories, insurance coverage,
and perceived or expressed patient wishes. Furthermore,
the current framework of prenatal screening and diagnos-
tic options for genetic conditions such as aneuploidy will
also affect whether providers adopt cffDNA testing; a
reluctance to accept novel technologies or a vested interest
in existing technologies may present barriers to wide-
spread implementation. Assessing provider values and atti-
tudes surrounding how this testing should be made
commercially available will be an essential step in ensuring
that the goals and characteristics of testing match the
objectives of its stakeholders.
Product uptake
Like many medical technologies, the interface between
end users and cffDNA testing for aneuploidy influences
the trajectory of its implementation (Figure 4). Questions
about how patients perceive and interpret benefits and
risks in their choice to use (or not to use) this testing are
critical. Potential benefits may include non-invasiveness,
earlier timing, and increased reliability over existing
screening tests. Personal reasons to decline cffDNA test-
ing are more difficult to tease apart but may include
objections to prenatal testing or selective termination of
pregnancy, either for any genetic condition or specifically
for a given aneuploidy; as with the refusal of other prena-
tal testing, these objections may stem from individual
moral judgments or experiences, familial, provider, or
social pressures, religious traditions, and broader cultural
attitudes [50-53]. The diagnostic capability of cffDNA
testing for aneuploidy will also inform how patients
reflect on the benefits and costs of this technology rela-
tive to existing screening and diagnostic tests. Costs and
accessibility of prenatal care or the availability of
resources to raise a child with a given aneuploidy may
additionally influence pregnant women at the time of
decision-making.
In addition, access to information about a technology
impacts uptake. In the past, DTC sex testing using
cffDNA has generated controversy when consumers,
who felt that they had received insufficient information
about the possibility of inaccurate results, brought a
class-action suit against the company offering the test
[54]. Negative publicity, and especially legal action, has
the potential to modify and even reverse the course of
implementation of cffDNA testing. Additionally, this
case elucidates the fact that the non-invasive nature and
thus modified benefit-risk calculation for cffDNA testing
may undermine the integrity of the informed consent
process, even when tests are provided solely through
healthcare professionals [55]. Given that pregnant
patients undergo a number of unrelated blood draws
during early pregnancy, there is evidence to suggest that
even trained professionals are not always thorough in
obtaining informed consent when the physical risks of a
test are so significantly reduced [56]. There is a concern
that patients, if unaware that they are undergoing prena-
tal testing, will feel that their autonomy and decision-
making has been compromised [57]. In order to avoid a
loss of trust in novel prenatal testing methodologies,
both healthcare providers - including obstetricians,
genetic counselors, specialized nurses, and other allied
health professionals - and potential patients need to be
educated about the nature and availability of cffDNA
testing. Stakeholders with whom we engaged addition-
ally recommended genetic counseling as a necessary
step in attaining the full engagement of patients in the
decision-making process, which is consistent with our
findings in the healthcare provider population [26].
Through coverage decisions, insurance agencies also
have the ability to influence how and whether cffDNA
testing for aneuploidy is accessed. One company cur-
rently offering cffDNA tests for trisomy 21 has set drasti-
cally differential prices ($1,900 as opposed to $235) for
consumers based on whether they have insurance cover-
age [17]. Many women may not be able to afford the out-
of-pocket expenses or may choose to decline more
expensive options when insurers already cover other
tests. Insurance programs will likely assess the cost-bene-
fit ratio of this technology in the context of the estab-
lished framework of prenatal screening and diagnostic
tests for aneuploidy. By exploring testing reliability, tim-
ing, and indications, insurers will determine whether
implementation is appropriate as a reimbursable primary
or secondary screening mechanism or as a diagnostic
technique. If a decision is made to not cover cffDNA
testing for aneuploidy, this testing may remain accessible
only to a wealthy few or never realize commercial success
at all. Regional mechanisms for offering testing to large
subsets of the population, such as the California Prenatal
Screening Program, must also be considered in determin-
ing the relevant stakeholders in the dissemination of this
technology. If state law requires the offering and coverage
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of cffDNA testing for all pregnant women seeking prena-
tal care, as California law currently requires for inte-
grated screening, uptake may be significantly increased.
If cffDNA testing for aneuploidy is found to be a cost-
effective, desirable prenatal technology, federal and state
reimbursement and dissemination strategies should strive
for equity in access across all appropriate patient
populations.
Legal context
Government agencies will play an important role in the
implementation of cffDNA testing for aneuploidy at sev-
eral translational stages (Figure 5). As a primary source
of funding for research on prenatal testing and a poten-
tial buyer of this testing (through state insurance agen-
cies), the government’s control over financial resources
has the potential to drive forward or inhibit develop-
ment and use of this technology. Judicial decisions also
have the potential to influence translational pathways
through pertinent legal cases, such as those involving
patenting and licensing, consumer interactions with
companies, or communications between patients and
healthcare providers by means of wrongful birth suits
[58,59]. For example, a recent lawsuit in Oregon
resulted in the awarding of several million dollars to
parents claiming to have otherwise ended a pregnancy
had they received an accurate prenatal diagnosis of tris-
omy 21; with new technologies like cffDNA testing
being made available, pressures will mount for physi-
cians to avoid liability by offering any and all tests to
ensure that affected pregnancies are detected [60].
Other stakeholders will have important influences over
the initiation and outcomes of such legal cases; for
example, in the aforementioned case involving Myriad
Genetics, physicians, patients, professional societies, and
community activists filed a suit that may influence the
legality of gene patenting. In the case of cffDNA testing
for aneuploidy, we have already started to witness a
surge of legal action pursued by various patent and
license holders that may critically influence the charac-
teristics of technological implementation [61].
Currently, government regulation of many genetic tests
does not extend beyond certification of clinical labora-
tories under the Clinical Laboratory Improvement
Amendments, administered by the Centers for Medicare
and Medicaid Services. However, the Food and Drug
Administration (FDA) has the authority to assign classifi-
cations (I, II, or III) to all medical devices and to apply
increasingly stringent standards for their regulation. His-
torically, the implicit endorsement of a technology under
FDA regulation has led to drastic consequences on
uptake; for example, it was only following FDA approval
of alpha-fetoprotein screening of maternal serum that
American Congress of Obstetricians and Gynecologists
issued its legal position that essentially assigned this
novel technology as the universal standard of care [49]. A
public determination has yet to be made regarding the
classification of cffDNA testing for aneuploidy. Given
public hearings and the sending of cease-and-desist let-
ters to a number of companies offering genetic tests,
including one company offering cffDNA testing for RhD
blood type, the FDA may intend to regulate this technol-
ogy as a medical device in the future [62,63]. Commer-
cially available medical devices require pre-market
notification or pre-market approval from the FDA and in
response, at least one firm developing cffDNA technology
has indicated that it intends to file for pre-market
approval of its trisomy 21 test [64]. Given the current
uncertainties of the regulatory environment, these gov-
ernment agencies have the ability to dictate the features
and course of implementation of aneuploidy testing
using cffDNA.
Social context
As with the introduction of other prenatal technologies,
campaigns that endorse or oppose the use of cffDNA test-
ing for aneuploidy are likely to originate among activist
communities, such as the disability rights community
(Figure 6) [65,66]. In particular, advocacy groups for speci-
fic genetic conditions, such as trisomy 21, raise significant
concerns about the underlying suggestion of prenatal test-
ing that disability is something to be avoided and suggest
that, while prenatal testing in and of itself may be accepta-
ble, discussions surrounding prenatal options must be
comprehensive, sensitive, and without undue pressures on
prospective parents. Another group with considerable
interest in this technology includes individuals who
oppose abortion and strongly disagree with any prenatal
technology that could lead to increased rates of pregnancy
termination. Equally relevant groups are feminist commu-
nities or other groups in civil society that campaign for
reproductive liberties, who may argue that pregnant
women have an inherent right to obtain fetal genetic infor-
mation via prenatal testing [67].
The influences of activism in multiple directions may
manifest in state legislation over the scope of lawful prena-
tal testing and pregnancy termination; current legislative
trends in the US include increasing restrictions on abor-
tion [68]. In the past, some of these communities have had
considerable impact on the course of research and transla-
tion of genetic technologies, through lobbying efforts,
provision of research funding, and educational activities
for the public and healthcare providers [67,70]. Moreover,
litigation brought by private citizens, such as the afore-
mentioned cases involving DTC cffDNA testing for fetal
sex or the validity of patents on BRCA genetic testing, may
allow the broader public to redirect future commercializa-
tion activities and uptake of these technologies [40,41,54].
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As with all realms, a balance must be struck between
allowing interest groups, including those whose voices are
often neglected, to be heard and preventing any one con-
stituency from wielding power to introduce genetic tech-
nologies that are ineffective or undesirable at a societal
level.
At the individual level, these social and political activities
may have sufficient influence to alter opinions, and thus
uptake, of this technology. To the individual, the debate
over whether prenatal testing or termination of pregnancy
for aneuploidy is morally acceptable and the appropriate
use of such information is rarely as dichotomized as it
may appear on the political stage. The application of per-
sonal values to novel reproductive choices is not clear cut;
pregnant women draw from intersecting and opposing
messages from their healthcare providers, family, religion,
culture, and society in facing such decisions [50-53].
Furthermore, families may seek prenatal test information
for many reasons other than deciding whether to termi-
nate a pregnancy; it has been an unfortunate consequence
that prenatal testing technologies are often only thought
of merely as precursors to selective abortions. In the
related history of the implementation of maternal serum
screening for aneuploidy, pregnant women often left dis-
cussions with their physicians concerned that a positive
screen or test result was assumed to be cause for termina-
tion of the pregnancy. Patients ended up being unclear
about the purposes or implications of screening given
either their doctors’ uncertainty about testing features or
the lack of comprehensive, clear, and culturally sensitive
communication and counseling before screening, particu-
larly in the context of their already-complex decision-mak-
ing processes surrounding uptake of this screening [52,71].
Given the parallels between cffDNA testing and this pre-
vious technology, we suggest that mechanisms be put in
place to encourage careful and complete discussions
among providers and prospective parents.
Ascertaining the attitudes of specific activist groups and
broader sets of stakeholders, including the general public,
and, to the greatest extent possible, aligning their objec-
tives within proposed translational pathways is critical to
the successful implementation of this technology. In addi-
tion, aggregate social attitudes towards cffDNA testing
may influence uptake; if this testing is perceived as pre-
senting new options to prospective parents, it is also possi-
ble that parents will be perceived as irresponsible for not
availing themselves of these options [72,73]. Such attitudi-
nal shifts may create a coercive environment for decision-
making.
Summary
Successful implementation of cffDNA testing for aneu-
ploidy should involve the consideration of potential
translational pathways and their consequences from the
perspective of diverse sets of stakeholders. For example,
it is critical to understand how these pathways will be
influenced by the values of pregnant women, their
families, and healthcare providers and mediated by the
agendas of judicial and regulatory bodies, payers, profes-
sional societies, educational systems, and representatives
from civil society. Throughout the translational course,
researchers and developers should solicit the early and
continued participation of these stakeholders in order to
ensure that their visions for the ultimate use of this test-
ing are compatible and avoid inefficient, inappropriate,
or otherwise unsuccessful attempts at translation. We
hope that our initial sketches of stakeholder interactions
will provide a framework in which the pathways to
implementation of this technology can be explored in
further detail via consultation and collaboration with an
array of stakeholders representing the six classes that we
have described. As part of a more comprehensive study
on stakeholder attitudes towards cffDNA technology, we
plan to develop an interactive forum whereby diverse
stakeholders, including those from traditionally underre-
presented categories, can express their values and opi-
nions and respond to the priorities of others; we urge
others to develop similar methodologies for engaging
stakeholders and presenting findings to those in posi-
tions to enact policies and practices that have achieved
consensus among stakeholders.
Moving forward with genomic medicine
Using cffDNA testing for aneuploidy as an example of
an emerging genomic technology, we have illustrated
how complex and uncertain translational pathways may
be. Analyzing the priorities and dynamics among stake-
holders may help to identify factors that may impact
implementation and achieve a true picture of technolo-
gical translation. Our assessment represents a departure
from conventional technology assessment methods,
which consider features inherent to the technology itself.
Such assessments generally limit the inclusion of stake-
holder values and lack critical historical perspectives.
The situation of cffDNA testing among both genetic and
reproductive technologies creates special demands on a
translational analysis of this sort, requiring attention to a
particularly wide scope of stakeholders and a rich history
of technological, social, and political successes and fail-
ures. While the features and contextual details of other
genomic technologies vary widely and must be consid-
ered on an individual basis, we argue that the successful
development and provision of any new technology must
be predicated on the flow of information and ideals sur-
rounding its real and desired features among all of its sta-
keholders. Utilizing this framework to trace and elaborate
upon translational pathways will, we believe, lead to the
translation of cffDNA testing for aneuploidy in the most
Sayres et al. Genome Medicine 2012, 4:49
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ethically sound manner. We hope that it may also pro-
vide a starting place for the consideration of other novel
technologies - with their own unique frameworks of
translational pathways - in order to achieve the goal of
genomic translation in the years to come.
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